Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease

Abstract

This is the first comprehensive review of the evidence base for the treatment of paediatric IBD, highlighting the paucity of trials of high methodological quality. As a result, the development of clinical guidelines for managing children and young people with IBD must be consensus based, informed by the best-available evidence from the paediatric literature and high-quality data from the adult IBD literature, together with the clinical expertise and multidisciplinary experience of paediatric IBD experts.

One-year prospective registry of inflammatory bowel disease in the Argentine pediatric population

“…[7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] The incidence in the Autonomous City of Buenos Aires was 2.4/100 000, closest to other reports, whereas a very low incidence was reported in the province of Buenos Aires, even lower than in other provinces. In Greater Buenos Aires, which comprises 24 districts, the same number of patients was registered in the same period as in the Autonomous City of Buenos Aires; however, the rate was low (0.4/100 000) due to the population size.…”

“…These findings were consistent with those published in the EUROKID registry from 2012. 1,[23][24][25] The small bowel series, a radiology test available in almost all facilities of Argentina, was performed in 40% of patients; this rate is much lower than what is recommended by the Porto criteria. 1 In relation to the extent and severity of UC, it affected the entire colon of most patients, and it was mild in 70% and moderate in 26%.…”

Registro prospectivo durante un año de enfermedad inflamatoria intestinal en población pediátrica argentina

“…[7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] La incidencia en la CABA alcanzó 2,4/100 000, más cercana a las reportadas, mientras la provincia de Buenos Aires reportó una incidencia muy baja, incluso, respecto a otras provincias del país. En el Gran Buenos Aires, que comprendió 24 partidos del conurbano, se registraron, durante el mismo período, igual número de pacientes que en la CABA, pero la tasa obtenida fue baja (0,4/100 000), debido al elevado número poblacional.…”

“…Todos estos resultados coincidieron con los publicados en el registro EUROKID del año 2012. 1,[23][24][25] El tránsito de intestino delgado, estudio radiológico disponible en casi todos los centros del país, fue realizado en 40% de los pacientes, valores muy por debajo de lo recomendado en los criterios Porto. 1 En cuanto a la extensión y gravedad de CU, la mayoría presentaron pancolitis; 70% fueron formas leves y 26%, moderadas.…”

Nutritional treatment in inflammatory bowel disease: An update

“…In fact, EN seems to exert a direct antiinflammatory effect on the intestinal mucosa by reducing IL-6 production and increasing insulin-like growth factor (IGF)-1 production (40). To date, no randomized controlled trials (RCTs) of EN versus a placebo have been conducted (41). However, EN has been proven to be effective in the treatment of the acute phase of CD, achieving remission rates from 20% to 84.2% regardless of disease location.…”